QNRX Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Quoin Pharmaceuticals Ltd.'s net margin of --. Quoin Pharmaceuticals Ltd.'s return on equity of -316.34% beat CEL-SCI Corp.'s return on equity of -266.61%.

Quoin Pharmaceuticals Ltd. has a consensus price target of $40.67, signalling upside risk potential of 236.37%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Quoin Pharmaceuticals Ltd., analysts believe CEL-SCI Corp. is more attractive than Quoin Pharmaceuticals Ltd..

Quoin Pharmaceuticals Ltd. has a beta of 1.589, which suggesting that the stock is 58.943% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Quoin Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quoin Pharmaceuticals Ltd. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Quoin Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Quoin Pharmaceuticals Ltd.'s net income of -$4M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Quoin Pharmaceuticals Ltd.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quoin Pharmaceuticals Ltd. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Quoin Pharmaceuticals Ltd.'s net margin of -953.4%. Quoin Pharmaceuticals Ltd.'s return on equity of -316.34% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Quoin Pharmaceuticals Ltd. has a consensus price target of $40.67, signalling upside risk potential of 236.37%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Quoin Pharmaceuticals Ltd., analysts believe IGC Pharma, Inc. is more attractive than Quoin Pharmaceuticals Ltd..

Quoin Pharmaceuticals Ltd. has a beta of 1.589, which suggesting that the stock is 58.943% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Quoin Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quoin Pharmaceuticals Ltd. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Quoin Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Quoin Pharmaceuticals Ltd.'s net income of -$4M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Quoin Pharmaceuticals Ltd.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quoin Pharmaceuticals Ltd. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to Quoin Pharmaceuticals Ltd.'s net margin of 21.47%. Quoin Pharmaceuticals Ltd.'s return on equity of -316.34% beat Johnson & Johnson's return on equity of 33.27%.

Quoin Pharmaceuticals Ltd. has a consensus price target of $40.67, signalling upside risk potential of 236.37%. On the other hand Johnson & Johnson has an analysts' consensus of $203.42 which suggests that it could grow by 0.74%. Given that Quoin Pharmaceuticals Ltd. has higher upside potential than Johnson & Johnson, analysts believe Quoin Pharmaceuticals Ltd. is more attractive than Johnson & Johnson.

Quoin Pharmaceuticals Ltd. has a beta of 1.589, which suggesting that the stock is 58.943% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Quoin Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.55% to investors and pays a quarterly dividend of $1.30 per share. Quoin Pharmaceuticals Ltd. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quoin Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Quoin Pharmaceuticals Ltd.'s net income of -$4M is lower than Johnson & Johnson's net income of $5.2B. Notably, Quoin Pharmaceuticals Ltd.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quoin Pharmaceuticals Ltd. is -- versus 5.31x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Protagonist Therapeutics, Inc. has a net margin of -- compared to Quoin Pharmaceuticals Ltd.'s net margin of -834.87%. Quoin Pharmaceuticals Ltd.'s return on equity of -316.34% beat Protagonist Therapeutics, Inc.'s return on equity of 7.15%.

Quoin Pharmaceuticals Ltd. has a consensus price target of $40.67, signalling upside risk potential of 236.37%. On the other hand Protagonist Therapeutics, Inc. has an analysts' consensus of $91.42 which suggests that it could grow by 1.16%. Given that Quoin Pharmaceuticals Ltd. has higher upside potential than Protagonist Therapeutics, Inc., analysts believe Quoin Pharmaceuticals Ltd. is more attractive than Protagonist Therapeutics, Inc..

Quoin Pharmaceuticals Ltd. has a beta of 1.589, which suggesting that the stock is 58.943% more volatile than S&P 500. In comparison Protagonist Therapeutics, Inc. has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.221%.

Quoin Pharmaceuticals Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagonist Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quoin Pharmaceuticals Ltd. pays -- of its earnings as a dividend. Protagonist Therapeutics, Inc. pays out -- of its earnings as a dividend.

Quoin Pharmaceuticals Ltd. quarterly revenues are --, which are smaller than Protagonist Therapeutics, Inc. quarterly revenues of $4.7M. Quoin Pharmaceuticals Ltd.'s net income of -$4M is higher than Protagonist Therapeutics, Inc.'s net income of -$39.3M. Notably, Quoin Pharmaceuticals Ltd.'s price-to-earnings ratio is -- while Protagonist Therapeutics, Inc.'s PE ratio is 141.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quoin Pharmaceuticals Ltd. is -- versus 27.49x for Protagonist Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.